Abstract:The main actions of metformin are as follows: To reduce hyperglycemia via the suppression of gluconeogenesis, improve glucose uptake and insulin sensitivity, and stimulate activation of adenosine monophosphate-activated protein kinase during the treatment of diabetes mellitus. It is well known that metformin acts via complex mechanisms, including multitarget and multipathway mechanisms; however, the multi-targeted antidiabetic genes of metformin remain obscure. The present study aimed to perform transcriptomic and proteomic analysis of potential therapeutic target genes in the liver of metformin-treated Sprague-Dawley rats with type 2 diabetes mellitus. The type 2 diabetes rat model was established using streptozotocin. Fasting blood glucose, hemoglobin A1c, serum insulin and biological parameters were subsequently measured. Differentially expressed genes (DEGs) and proteins were identified in the rat livers by expression profile analysis and isobaric tags for relative and absolute quantitation (iTRAQ). A 1.5-fold alteration in gene expression, as determined using chip-based expression profile analysis, and a 1.2-fold alteration in protein expression, as determined using iTRAQ, were considered physiologically significant benchmarks, which were used to identify DEGS in metformin-treated rats with type 2 diabetes mellitus. The DEGs were verified using quantitative polymerase chain reaction (qPCR) and western blot analysis. Numerous hepatic genes involved in various metabolic pathways were affected by metformin; in particular, genes associated with lipid metabolism were markedly affected. Expression profile analysis and iTRAQ analysis suggested that carboxylesterase 1C subunit (Ces1C) and cholesterol 7-hydroxylyase (Cyp7a1) may serve as important DEGs, which were validated by qPCR and western blot analysis. Ces1C and Cyp7a1 are the main enzymes in cholesterol metabolism, yet the result of western blotting was not consistent with qPCR. The present study demonstrated that metformin may affect the expression of numerous hepatic genes involved in metabolic pathways, particularly the lipid and cholesterol metabolic pathways. Ces1C and Cyp7a1 may be considered novel therapeutic target genes in the liver, which are involved in the antidiabetic effects of metformin.

Research Progress of Metformin in the Treatment of Liver Fibrosis.

Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms

Research progress of metformin in the treatment of non-alcoholic fatty liver disease

[Research Advances in the Treatment of Hepatic Fibrosis].

Metformin exerts anti-liver fibrosis effect based on the regulation of gut microbiota homeostasis and multi-target synergy

Transcriptomic and Proteomic Analysis of Potential Therapeutic Target Genes in the Liver of Metformin‑treated Sprague‑Dawley Rats with Type 2 Diabetes Mellitus

Mitigation of Liver Fibrosis Via Hepatic Stellate Cells Mitochondrial Apoptosis Induced by Metformin

Metformin Attenuates Hepatic Fibrosis in Mice by Altering the Gut Microbiota

Metformin improves fibroblast metabolism and ameliorates arthrofibrosis in rats

Metformin: update on mechanisms of action on liver diseases

Metformin ameliorates liver fibrosis induced by congestive hepatopathy via the mTOR/HIF-1α signaling pathway

Advance of Metformin in Liver Disease

Liver Fibrosis: Therapeutic Targets and Advances in Drug Therapy

Deciphering the Antifibrotic Property of Metformin

Metformin Alleviates Arthrofibrosis via Fibroblast Metabolic Reprogramming

Recent advances in molecular magnetic resonance imaging of liver fibrosis.

Metformin Induces Mitochondrial Fission and Reduces Energy Metabolism by Targeting Respiratory Chain Complex I in Hepatic Stellate Cells to Reverse Liver Fibrosis.

Research Progress in Mechanism and Treatment of Hepatic Fibrosis

Mechanisms and Treatment of Liver Fibrosis

Research progress in drugs for anti-hepatic fibrosis

Metformin and Metabolic Diseases: a Focus on Hepatic Aspects.